NASDAQ · BCDAW
BioCardia, Inc.
Healthcare · Biotechnology
$0.01
Down-$0.00 (-3.17%)
Updated Aug 13, 2026, 11:09 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 10.12K
- P/E ratio
- -1,087.96
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 18.71K
- Avg. volume
- 0
Price performance
BCDAW price history
1M range · 0 trading sessions · Daily adjusted prices
BCDAW does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest BCDAW news
The latest Smart Investors Daily articles mentioning BCDAW.
Stock researchCompany · Overview
BCDAW research
Overview
Company profile and research snapshot.
Company profile
BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
